Thomas Watkins - Horizon Pharma Independent Director

Mr. H. Thomas Watkins is Independent Director of the Company. Mr. Watkins, in his most recent role, was director, president and chief executive officer of Human Genome Sciences, Inc., a public biopharmaceutical company, from 2004 until HGS was acquired by GlaxoSmithKline in 2012. Before leading HGS, Mr. Watkins spent over twenty years in senior roles at Abbott Laboratories and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately 2 billion to over 4 billion in annual revenue. Mr. Watkins began his career in 1974 with Arthur Andersen Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan. Mr. Watkins holds a bachelors degree from the College of William and Mary, and a masters degree in business administration from the University of Chicago Graduate School of Business. Mr. Watkins is the chairman of the board of directors of Vanda Pharmaceuticals, Inc., a public biotechnology company. He is also a member of the board of directors of HemoShear Therapeutics, LLC, a private biotechnology company, and the Biotechnology Innovation Organization and is vicechair of the board of visitors of The College of William and Mary. since 2014.